Haleon Plc: 2024 Annual Report (Form 20-F) Summary
Business Context and Reporting Period
Company: Haleon Plc
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Haleon is a global leader in the consumer healthcare market, operating across five categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, and Digestive Health and Other. The company operates as a standalone entity following its demerger from GSK in 2022, with a strategy focused on increasing household penetration, capitalizing on emerging opportunities, maintaining financial discipline, and running a responsible business.
Key Financial Metrics
| Metric | 2024 Value | 2023 Value | Change |
|---|---|---|---|
| Revenue | £11.23 billion | £11.30 billion | (0.6)% |
| Organic Revenue Growth | 5.0% | 8.0% | (3.0) ppts |
| Operating Profit | £2.21 billion | £2.00 billion | 10.5% |
| Adjusted Operating Profit | £2.50 billion | £2.55 billion | (1.9)% |
| Organic Operating Profit Growth | 9.8% | 10.8% | (1.0) ppts |
| Profit After Tax (Attributable to Shareholders) | £1.44 billion | £1.05 billion | 37.5% |
| Diluted EPS | 15.7p | 11.3p | 38.9% |
| Adjusted Diluted EPS | 17.9p | 17.3p | 3.5% |
| Free Cash Flow | £1.94 billion | £1.58 billion | 23.0% |
| Net Debt | £7.91 billion | £8.51 billion | (7.0)% |
| Net Debt / Adjusted EBITDA | 2.8x | 3.0x | (0.2)x |
Material Changes vs. Prior Period
- Revenue Decline: Reported revenue decreased 0.6% primarily due to adverse foreign exchange impacts (-3.7%) and net M&A impacts (-1.9%) from the divestment of the Nicotine Replacement Therapy (NRT) business outside the US and the ChapStick brand. Organic revenue grew 5.0%.
- Profitability: Operating profit increased 10.5% driven by operating leverage and efficiencies, though Adjusted Operating Profit declined 1.9% on a reported basis due to FX and M&A. On an organic basis, Adjusted Operating Profit grew 9.8%.
- EPS Growth: Diluted EPS rose significantly by 38.9% to 15.7p, driven by lower dividend payments to the China Joint Venture and the impact of a £500 million share buyback program which reduced the weighted average share count by 1%.
- Portfolio Management: The company divested the NRT business outside the US (realizing a £121m gain) and the ChapStick brand. It also increased its stake in the Tianjin TSKF Pharmaceutical Co. Ltd. (TSKF) joint venture in China from 55% to 88% for approximately £500m.
- Shareholder Returns: Returned over £1.1 billion to shareholders in 2024 via dividends and share buybacks. The Board proposed a 10% increase in the total dividend to 6.6p per share.
Guidance, Outlook, and Risks
- Medium-Term Guidance: Haleon expects annual organic revenue growth of 4-6% and organic operating profit growth ahead of organic revenue growth. The target leverage is around 2.5x net debt/adjusted EBITDA.
- 2025 Outlook: Management expects to deliver organic revenue growth of 4-6% in 2025. The Board has allocated an additional £500 million for share buybacks in 2025.
- Key Risks:
- Geopolitical Instability: Risks related to conflicts in the Middle East and Ukraine, and tensions between the US and China, impacting supply chains and trade.
- Cyber Security: Increased sophistication of cyber threats and reliance on digital services.
- Supply Chain Resilience: Disruptions from extreme weather, raw material availability, and logistics constraints.
- Regulatory & Ingredient Risks: Scrutiny of ingredients (e.g., talc, Zantac legacy issues) and evolving ESG regulations.
- Unusual Items: The filing includes a £135m impairment charge for the Nexium brand due to challenging market conditions. Additionally, the company applied IAS 29 (Hyperinflationary Economies) to Argentina and Turkey effective January 1, 2024, resulting in a £6m net monetary gain.
Important Facts for Investors to Verify
- China Joint Venture (TSKF): Verify the integration progress and financial performance of the TSKF joint venture following the increase in ownership to 88% and the option to acquire the remaining 12% in 2025.
- Share Buyback Execution: Monitor the execution of the £500 million share buyback allocation for 2025 and its impact on earnings per share.
- Dividend Sustainability: Assess the sustainability of the proposed 10% dividend increase (to 6.6p) in the context of the company's free cash flow generation and debt reduction targets.
- FX Sensitivity: Evaluate the impact of currency fluctuations, particularly the strengthening of Sterling against the USD and Euro, on future reported revenue and profit figures.
- Brand Impairments: Monitor the performance of the Nexium brand and other indefinite-life intangible assets for potential future impairment charges given the sensitivity to market conditions.